Moderna joins Nasdaq-100 after 700% run this year
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
Moderna has been added to the Nasdaq-100 index, a move that puts the stock on more investors' radars and prompts institutional buying. The inclusion follows a roughly 700% run this year, driven by FDA approvals for an updated COVID-19 vaccine and a new flu vaccine, plus promising phase 3 results for its cancer vaccine candidate.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.